Literature DB >> 7660152

Preliminary data from a field trial of the PFA-100 system.

E F Mammen1, R S Alshameeri, P C Comp.   

Abstract

The PFA-100 system (Dade International Inc., Miami, FL) is a platelet function analyzer, the design of which is based on the technology of the Thrombostat 4000 VDG, Seeon, Germany. It was developed to measure primary, platelet dependent hemostasis in citrated whole blood in vitro. A first pilot study was conducted with the instrument to assess performance characteristics. Healthy subjects (normals) who had not ingested any medications, and patients (abnormals) with primary, platelet-related hemostasis defects, which included users of aspirin, were studied with two test cartridges; collagen/ADP and collagen/epinephrine. Before the study certain variables were tested that ascertained that blood drawn into either 3.8% or 3.2% sodium citrate containing vacutainers (rather than syringes) could be used for testing. Tests must be performed within a five-hour time span from drawing to testing, and blood must be kept at room temperature. Normal reference values were 77-133 seconds closure times for collagen/ADP and 98-185 seconds for collagen/epinephrine. Precision testing revealed a CV of < 10% for within-day and between-day (five days) analyses on collagen/ADP cartridges and a CV of 5-14% for both runs on the collagen/epinephrine cartridges. No clinically important differences were found between measurements in the two positions of the instrument, although one follows the other.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7660152     DOI: 10.1055/s-0032-1313613

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  13 in total

Review 1.  Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.

Authors:  J J Ferguson; M Zaqqa
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

3.  The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.

Authors:  Burak Pamukcu; Huseyin Oflaz; Rezzan Deniz Acar; Sabahattin Umman; Nevres Koylan; Berrin Umman; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

4.  Evaluation of platelet function in aspirin treated patients with CAD.

Authors:  Marlene S Williams; Thomas S Kickler; Dhananjay Vaidya; Ladina S Ng'alla; David E Bush
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 5.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

Review 6.  A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes.

Authors:  Burak Pamukcu
Journal:  J Thromb Thrombolysis       Date:  2006-12-22       Impact factor: 2.300

7.  The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.

Authors:  Burak Pamukcu; Huseyin Oflaz; Aytac Oncul; Berrin Umman; Fehmi Mercanoglu; Mustafa Ozcan; Mehmet Meric; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

8.  Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.

Authors:  Christopher N Floyd; Timothy Goodman; Silke Becker; Nan Chen; Agnesa Mustafa; Emma Schofield; James Campbell; Malcolm Ward; Pankaj Sharma; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

9.  Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.

Authors:  Ebru Tirnaksiz; Burak Pamukcu; Huseyin Oflaz; Yilmaz Nisanci
Journal:  J Thromb Thrombolysis       Date:  2007-10-05       Impact factor: 2.300

Review 10.  [Rational hemostatic screening].

Authors:  N Maurin
Journal:  Med Klin (Munich)       Date:  1999-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.